Published 1 day ago • loading... • Updated 1 day ago
Aclaris Therapeutics Announces Top Line Phase 2 Results for its Anti-TSLP Monoclonal Antibody Bosakitug (ATI-045) in Atopic Dermatitis (AD) - PressReach
– The ADMIRATION Trial Did Not Achieve its Primary Endpoint of Percent Change in Eczema Area and Severity Index (EASI) Score from Baseline at Week 24 – – Aclaris Remains Focused on Prioritizing the Development of its Oral Kinase (ITK) Inhibitors and Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 – WAYNE, Pa., Nov. 16, 2026 (GLOBE NEWSWIRE) — … Continue reading "Aclaris Therapeutics Announces Top Line Phase 2 Results for its Anti-TSLP Monoclonal An…
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.